Affinage

TNFAIP2

Tumor necrosis factor alpha-induced protein 2 · UniProt Q03169

Length
654 aa
Mass
72.7 kDa
Annotated
2026-06-10
40 papers in source corpus 19 papers cited in narrative 19 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 5/5 claims corpus-supported (100%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

TNFAIP2 is a cytosolic, actin-associated effector that couples inflammatory and oncogenic transcriptional programs to cytoskeletal remodeling, membrane dynamics, and redox signaling, thereby promoting cell migration, invasion, and intercellular communication (PMID:26189798, PMID:23975427). As a transcriptional output of NF-κB (downstream of EBV LMP1/p65, Legionella infection), KLF5, STAT1/EP300, and PML-RARα, its expression is induced by diverse inflammatory and differentiation cues and is further tuned post-transcriptionally by miR-184 and by inhibitory upstream ORFs that are released during macrophage differentiation (PMID:23975427, PMID:27130431, PMID:34112215, PMID:10766166, PMID:21934093, PMID:31392347). Mechanistically, TNFAIP2 binds and activates the small GTPases Rac1 and Cdc42 to drive actin-based protrusions and motility, in part through an IQGAP1/Integrin β4 scaffold, and a Rac1→ERK→AP-1→HIF1α axis links this activity to tumor angiogenesis (PMID:26189798, PMID:37787041, PMID:39532855). Through a DLG motif it directly binds the Kelch domain of KEAP1, competing with NRF2 to stabilize NRF2 and suppress ROS-JNK signaling (conferring cisplatin resistance) and competing for KEAP1 to protect IKKβ from K63-ubiquitination, thereby sustaining NF-κB signaling (PMID:37525222, PMID:39948570). TNFAIP2 also acts at membranes: it binds PIP2 to promote CSF1R clustering and, via RalA and the exocyst complex, enhances CSF1R surface trafficking in macrophages (PMID:39939179, PMID:41158107); it is required for tunneling-nanotube–mediated transfer of autophagosomes and lysosomes between cells (PMID:35659195); and it acts epistatically upstream of vimentin to control triacylglycerol and lipid-droplet synthesis during stem-cell differentiation (PMID:33300287).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 2000 Medium

    Established TNFAIP2 (B94) as an immediate transcriptional target, defining it as a rapidly inducible gene wired to differentiation signaling.

    Evidence cDNA microarray and qRT-PCR with actinomycin D/cycloheximide controls and dominant-negative PML-RARα mutant in APL cell lines

    PMID:10766166

    Open questions at the time
    • Did not define the protein's biochemical activity
    • Promoter elements mediating PML-RARα-dependent induction not mapped
  2. 2011 Medium

    Showed TNFAIP2 is post-transcriptionally repressed by miR-184, revealing a layer of expression control disrupted by a 3'-UTR SNP.

    Evidence Luciferase reporter assays with WT/variant 3'-UTR and genotype-mRNA correlation in patient PBMCs

    PMID:21934093

    Open questions at the time
    • Functional consequence of altered TNFAIP2 levels not tested here
    • Did not address protein function
  3. 2013 High

    Connected NF-κB transcriptional induction to TNFAIP2 protein function, showing LMP1/p65 induces TNFAIP2, which associates with actin to drive membrane protrusions and motility.

    Evidence Luciferase reporter and promoter mapping, p65 knockdown/overexpression, Co-IP, immunofluorescence, transwell migration in EBV context

    PMID:23975427

    Open questions at the time
    • Direct mechanism of actin engagement not resolved
    • Did not identify GTPase intermediates
  4. 2015 High

    Defined the core motility mechanism: TNFAIP2 binds and activates Rac1 and Cdc42 to remodel actin, downstream of KLF5.

    Evidence Reciprocal Co-IP, GTPase activity assays, siRNA migration/invasion readouts, KLF5 promoter reporter in multiple cancer lines

    PMID:26189798

    Open questions at the time
    • Whether TNFAIP2 acts as a direct GEF or via a scaffold not established
    • Structural basis of GTPase binding unknown
  5. 2015 Medium

    Identified an autoinhibitory role in early TNFα signaling, complicating the simple pro-NF-κB picture and linking a regulatory variant to septic shock outcome.

    Evidence NF-κB reporter and IL-8 assays with TNFAIP2 modulation, genetic association in two patient cohorts

    PMID:26347487

    Open questions at the time
    • Mechanism of NF-κB inhibition not defined
    • Apparent contradiction with later pro-NF-κB findings unreconciled
  6. 2016 Medium

    Showed pathogen-driven, NF-κB/chromatin-dependent induction of TNFAIP2 supports intracellular bacterial replication, casting it as a host factor exploited by infection.

    Evidence ChIP-seq for H4 acetylation, NF-κB inhibition, siRNA knockdown, intracellular L. pneumophila replication assay in A549 cells

    PMID:27130431

    Open questions at the time
    • Molecular step in bacterial replication supported by TNFAIP2 unknown
    • Single lab
  7. 2019 High

    Revealed uORF-dependent translational control as a gate on TNFAIP2 protein output during monocyte-to-macrophage differentiation.

    Evidence Luciferase reporters with mutant uORFs, polysome profiling, TPA stimulation, monocyte vs. macrophage comparison

    PMID:31392347

    Open questions at the time
    • Trans-acting factors controlling uORF inactivation not identified
  8. 2020 High

    Uncovered a metabolic function: TNFAIP2 acts epistatically upstream of vimentin to drive triacylglycerol/lipid-droplet synthesis required for stem-cell differentiation.

    Evidence Tnfaip2 KO ESCs, lipidomics, Vim epistasis, palmitic acid rescue, planarian Smed-exoc3 cross-species validation

    PMID:33300287

    Open questions at the time
    • Biochemical link between TNFAIP2 and lipid synthesis enzymes unknown
    • How vimentin executes the downstream step unclear
  9. 2021 Medium

    Defined an epigenetic input: phospho-STAT1 recruits EP300 to H3K27ac enhancers to activate TNFAIP2 transcription.

    Evidence ChIP-PCR for STAT1/H3K27ac, STAT1-EP300 Co-IP, EP300 inhibition in DSS colitis model

    PMID:34112215

    Open questions at the time
    • Single lab
    • Downstream functional consequence of STAT1-driven TNFAIP2 not fully resolved
  10. 2022 High

    Established TNFAIP2 (M-Sec) as required for tunneling-nanotube formation enabling intercellular organelle transfer, with in vivo protection against diabetic nephropathy.

    Evidence Tnfaip2 KO mice (STZ-induced DN), live-cell organelle-transfer imaging, knockdown and overexpression rescue, lysosomal assays in podocytes

    PMID:35659195

    Open questions at the time
    • Molecular mechanism by which TNFAIP2 nucleates TNTs not defined
    • Link to GTPase/membrane functions not integrated
  11. 2023 High

    Identified the KEAP1-NRF2 competition mechanism: TNFAIP2's DLG motif binds KEAP1's Kelch domain to stabilize NRF2 and suppress ROS-JNK, conferring chemoresistance.

    Evidence Co-IP/MS, DLG-motif mutant analysis, flow cytometry for ROS/apoptosis, xenografts, siRNA knockdown

    PMID:37525222

    Open questions at the time
    • Whether DLG-KEAP1 binding regulates other KEAP1 substrates not addressed at the time
    • Structure of the complex not solved
  12. 2023 Medium

    Extended the GTPase mechanism by showing an Integrin β4/TNFAIP2/IQGAP1 axis activates Rac1 to confer DNA-damage drug resistance.

    Evidence Reciprocal Co-IP of IQGAP1 and Integrin β4, functional drug-resistance assays, siRNA in TNBC

    PMID:37787041

    Open questions at the time
    • Single lab
    • Direct binding interfaces among the three proteins not mapped
  13. 2024 Medium

    Linked TNFAIP2's GTPase activity to angiogenesis through a Rac1→ERK→AP-1→HIF1α transcriptional cascade.

    Evidence ChIP for AP-1 on HIF1α promoter, luciferase reporter, ERK inhibition, Rac1 activity assay, xenograft

    PMID:39532855

    Open questions at the time
    • Single lab
    • Quantitative contribution of this axis to in vivo angiogenesis not isolated
  14. 2025 High

    Showed TNFAIP2 binds PIP2 to cluster CSF1R and uses RalA/exocyst to traffic CSF1R to the surface, amplifying macrophage CSF-1 responses.

    Evidence PIP2-binding motif mutagenesis on TNFAIP2 and CSF1R, PIP2 depletion, RalA knockdown, exocyst perturbation, surface-trafficking and activation assays (two consecutive studies)

    PMID:39939179 PMID:41158107

    Open questions at the time
    • Whether PIP2 binding underlies TNFAIP2's other membrane functions (TNTs, GTPase activation) not tested
    • Structural basis of PIP2 recognition unresolved
  15. 2025 Medium

    Resolved the pro-NF-κB arm: TNFAIP2 competitively binds KEAP1 to protect IKKβ from K63-ubiquitination, sustaining NF-κB to drive EMT and lymphangiogenesis.

    Evidence Co-IP, ubiquitination Western blots, conditional KO mice in 4NQO-induced OSCC

    PMID:39948570

    Open questions at the time
    • Single lab
    • Relationship to the earlier reported NF-κB autoinhibition not reconciled

Open questions

Synthesis pass · forward-looking unresolved questions
  • It remains unresolved how TNFAIP2's distinct biochemical activities — GTPase activation, KEAP1/DLG competition, PIP2/membrane binding, and TNT formation — are integrated into one structural/regulatory framework, and whether they reflect context-specific modules of a single mechanism.
  • No structure of TNFAIP2 or its complexes reported
  • Domain-level mapping of the multiple binding functions incomplete
  • Apparent contradictory roles in NF-κB signaling not reconciled

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0008092 cytoskeletal protein binding 3 GO:0098772 molecular function regulator activity 3 GO:0008289 lipid binding 2 GO:0060090 molecular adaptor activity 2
Localization
GO:0005886 plasma membrane 3 GO:0005829 cytosol 2 GO:0005856 cytoskeleton 2 GO:0005811 lipid droplet 1
Pathway
R-HSA-162582 Signal Transduction 3 R-HSA-1643685 Disease 3 R-HSA-168256 Immune System 3 R-HSA-1266738 Developmental Biology 1 R-HSA-8953897 Cellular responses to stimuli 1
Partners
CDC42CSF1RIKBKBIQGAP1ITGB4KEAP1RAC1RALA
Complex memberships
exocyst

Evidence

Reading pass · 19 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2015 TNFAIP2 interacts with the small GTPases Rac1 and Cdc42, increasing their activities to remodel the actin cytoskeleton and change cell morphology, thereby promoting cancer cell migration and invasion downstream of KLF5 transcriptional activation. Co-immunoprecipitation, GTPase activity assays, siRNA knockdown with migration/invasion readouts, luciferase reporter assay for KLF5 binding to TNFAIP2 promoter Oncogene High 26189798
2013 EBV oncoprotein LMP1 transcriptionally induces TNFAIP2 expression via its CTAR2 domain through NF-κB (p65), acting on a newly identified NF-κB binding site at −3,869 to −3,860 bp of the TNFAIP2 promoter. TNFAIP2 then associates with actin and promotes formation of actin-based membrane protrusions and cell motility. Luciferase reporter assay, siRNA knockdown of p65, ectopic p65 expression, co-immunoprecipitation, immunofluorescence microscopy, transwell migration assay Oncogene High 23975427
2023 TNFAIP2 directly binds the Kelch domain of KEAP1 via its DLG motif, competing with NRF2 for KEAP1 binding, thereby preventing NRF2 from undergoing ubiquitin-proteasome degradation and resulting in NRF2 accumulation that inhibits ROS-mediated JNK phosphorylation and confers cisplatin resistance. Co-immunoprecipitation coupled with mass spectrometry (Co-IP/MS), Western blot, flow cytometry (ROS/apoptosis), xenograft mouse models, siRNA knockdown Journal of experimental & clinical cancer research High 37525222
2023 TNFAIP2 interacts with IQGAP1 and Integrin β4; Integrin β4 activates Rac1 through the TNFAIP2/IQGAP1 axis to confer DNA damage-related drug resistance in triple-negative breast cancer. Co-immunoprecipitation, functional drug resistance assays, siRNA knockdown eLife Medium 37787041
2025 TNFAIP2 promotes CSF1R aggregate/cluster formation and dimerization in macrophages by binding cellular PIP2; the PIP2-binding motif on TNFAIP2 (and on CSF1R) is required for aggregate formation. TNFAIP2 also enhances CSF1R trafficking to the cell surface via RalA and the exocyst complex, increasing macrophage functional response to CSF-1. Knockdown/overexpression in 293T and macrophage cells, PIP2 depletion experiments, mutation of PIP2-binding motifs, CSF1R activation assays, exocyst complex perturbation Life science alliance High 39939179
2025 TNFAIP2 enhances CSF1R trafficking to the cell surface and clustering via PIP2, RalA, and the exocyst complex, providing an additional mechanism by which TNFAIP2 increases macrophage response to CSF-1 beyond CSF1R clustering alone. PIP2-binding site mutagenesis of TNFAIP2 and CSF1R, RalA knockdown, exocyst complex inhibition, cell-surface CSF1R trafficking assays Journal of leukocyte biology High 41158107
2022 TNFAIP2 (M-Sec) is required for tunneling nanotube (TNT) formation in podocytes, enabling transfer of autophagosomes and lysosomes between cells; tnfaip2 knockout in mice exacerbates diabetic nephropathy, podocyte injury, and lysosomal dysfunction, demonstrating a protective role through TNT-mediated organelle exchange. Tnfaip2 knockout mice (streptozotocin-induced DN model), live-cell imaging of organelle transfer, siRNA knockdown, Tnfaip2 overexpression, lysosomal function assays Autophagy High 35659195
2021 STAT1 epigenetically regulates TNFAIP2 expression by recruiting the acetyltransferase EP300 to H3K27ac-enriched enhancer loci of TNFAIP2; phosphorylated STAT1 binds these enhancer regions and EP300 subsequently promotes TNFAIP2 transcription. ChIP-PCR for STAT1 and H3K27ac, co-immunoprecipitation of STAT1 and EP300, EP300 inhibitor experiments in DSS-induced colitis mouse model Clinical epigenetics Medium 34112215
2020 Tnfaip2 acts epistatically upstream of vimentin (Vim) to control triacylglycerol (TAG) and lipid droplet synthesis; Tnfaip2-deficient embryonic stem cells fail to induce TAG and lipid droplet formation during differentiation, and supplementation with palmitic acid rescues the differentiation defect, establishing a role for Tnfaip2 in lipid metabolism-driven stem cell differentiation. Tnfaip2 knockout ESCs, lipidomic analysis, epistasis experiments with Vim, palmitic acid supplementation rescue, planarian Smed-exoc3 knockdown for in vivo confirmation EMBO reports High 33300287
2019 TNFAIP2 translation is tightly suppressed by inhibitory upstream open reading frames (uORFs) in its transcript leader sequence; during monocyte-to-macrophage differentiation, these uORFs are inactivated, enabling a large increase in TNFAIP2 protein expression despite stable mRNA, revealing uORF-dependent translational control. Luciferase reporter assays with mutant uORF constructs, polysome profiling, stimulus-based overcoming of uORF inhibition (TPA), comparison of monocytes vs. mature macrophages Cellular and molecular life sciences High 31392347
2015 TNFAIP2 inhibits NF-κB activity and downstream IL-8 production early in the TNFα response, acting as an autoinhibitor of TNFα signaling; a genetic variant (rs8126) that increases TNFAIP2 expression reduces IL-8 and is associated with decreased survival in septic shock. NF-κB reporter assays, IL-8 measurement, in vitro TNFα stimulation with TNFAIP2 modulation, genetic association in two patient cohorts Journal of innate immunity Medium 26347487
2016 TNFAIP2 expression in human macrophages is induced by Legionella pneumophila infection in an NF-κB-dependent manner (H4 acetylation at its promoter); TNFAIP2 knockdown reduces intracellular replication of L. pneumophila, identifying it as a pro-bacterial host factor. Chromatin immunoprecipitation-sequencing (H4 acetylation), NF-κB inhibition, siRNA knockdown, intracellular bacterial replication assay in A549 cells The Journal of infectious diseases Medium 27130431
2024 TNFAIP2 promotes HIF1α transcription in breast cancer by sequentially activating Rac1 and ERK, which then activate AP-1 (c-Jun/Fra1); AP-1 directly binds the HIF1α promoter to enhance its transcription and drive tumor angiogenesis. Chromatin immunoprecipitation (AP-1 binding to HIF1α promoter), luciferase reporter assay, ERK inhibitor experiments, Rac1 activity assay, in vivo xenograft Cell death & disease Medium 39532855
2025 TNFAIP2 protects IKKβ from ubiquitin-proteasome degradation (ubiquitination at K63) by competitively binding KEAP1, thereby sustaining NF-κB signaling and promoting EMT and lymphangiogenesis in oral squamous cell carcinoma. Co-immunoprecipitation, Western blot for ubiquitination, conditional knockout mouse model with 4NQO-induced OSCC, gene enrichment analysis Cell communication and signaling Medium 39948570
2017 TNFAIP2 knockdown in esophageal squamous cell carcinoma cells decreases expression of downstream Wnt/β-catenin targets (c-Myc, cyclin D1, MMP-7, Snail) and upregulates E-cadherin and p-GSK-3β, placing TNFAIP2 upstream of Wnt/β-catenin signaling. Lentiviral RNAi knockdown, Western blot for Wnt pathway components, proliferation/invasion assays Oncology reports Low 28393234
2019 TNFAIP2 knockdown in platinum-resistant urothelial carcinoma cells upregulates E-cadherin and downregulates TWIST1, reversing EMT; global gene expression analysis after TNFAIP2 knockdown identified MTDH as a positive regulator of TNFAIP2-driven EMT. siRNA knockdown, microarray gene expression analysis, Western blot for EMT markers Laboratory investigation Low 31263157
2025 TGF-β increases acetylation of KLF5 (Ac-KLF5) in nasopharyngeal carcinoma cells; acetylated KLF5 directly binds the TNFAIP2 promoter and drives its transcription, inducing EMT; the pro-migratory/invasive effects of Ac-KLF5 depend on TNFAIP2. ChIP assay (KLF5 binding to TNFAIP2 promoter), Western blot for Ac-KLF5, siRNA knockdown of TNFAIP2, in vivo NPC mouse model Experimental cell research Medium 40054652
2000 B94/TNFAIP2 is rapidly induced by retinoic acid at the transcriptional level in a PML-RARα-dependent manner in APL cells: induction occurs within 1 hour, does not require new protein synthesis, and is blocked by actinomycin D; PML coiled-coil domain deletion abolishes induction, positioning TNFAIP2 as a transcriptional target downstream of PML-RARα. cDNA microarray, quantitative RT-PCR with actinomycin D and cycloheximide controls, RA treatment of NB4/UF1/HL-60/TF1-PR cells, dominant-negative PML-RARα deletion mutant Cancer research Medium 10766166
2011 A SNP in the miR-184 seed-binding site of the TNFAIP2 3′-UTR (rs8126 T>C) reduces luciferase reporter activity and is associated with lower endogenous TNFAIP2 mRNA levels, demonstrating that miR-184 post-transcriptionally represses TNFAIP2 and that this SNP disrupts the regulation. Luciferase reporter assay with WT and variant 3′-UTR constructs, genotype-phenotype mRNA analysis in patient PBMCs Carcinogenesis Medium 21934093

Source papers

Stage 0 corpus · 40 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2015 KLF5 promotes breast cancer proliferation, migration and invasion in part by upregulating the transcription of TNFAIP2. Oncogene 129 26189798
2022 Protective effect of the tunneling nanotube-TNFAIP2/M-sec system on podocyte autophagy in diabetic nephropathy. Autophagy 87 35659195
2018 The roles of TNFAIP2 in cancers and infectious diseases. Journal of cellular and molecular medicine 80 30145807
2015 MicroRNA-184 inhibits cell proliferation and invasion, and specifically targets TNFAIP2 in Glioma. Journal of experimental & clinical cancer research : CR 68 25888093
2000 Identification of B94 (TNFAIP2) as a potential retinoic acid target gene in acute promyelocytic leukemia. Cancer research 65 10766166
2011 A functional variant at the miR-184 binding site in TNFAIP2 and risk of squamous cell carcinoma of the head and neck. Carcinogenesis 64 21934093
2013 NF-κB-mediated transcriptional upregulation of TNFAIP2 by the Epstein-Barr virus oncoprotein, LMP1, promotes cell motility in nasopharyngeal carcinoma. Oncogene 62 23975427
1994 B94, a primary response gene inducible by tumor necrosis factor-alpha, is expressed in developing hematopoietic tissues and the sperm acrosome. The Journal of biological chemistry 62 8106408
2010 A novel role for TNFAIP2: its correlation with invasion and metastasis in nasopharyngeal carcinoma. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 50 21057457
2023 TNFAIP2 confers cisplatin resistance in head and neck squamous cell carcinoma via KEAP1/NRF2 signaling. Journal of experimental & clinical cancer research : CR 40 37525222
2017 Downregulation of TNFAIP2 suppresses proliferation and metastasis in esophageal squamous cell carcinoma through activation of the Wnt/β-catenin signaling pathway. Oncology reports 34 28393234
2021 STAT1 epigenetically regulates LCP2 and TNFAIP2 by recruiting EP300 to contribute to the pathogenesis of inflammatory bowel disease. Clinical epigenetics 33 34112215
2013 The miR-184 binding-site rs8126 T>C polymorphism in TNFAIP2 is associated with risk of gastric cancer. PloS one 32 23724109
2018 miR-221 alleviates the inflammatory response and cell apoptosis of neuronal cell through targeting TNFAIP2 in spinal cord ischemia-reperfusion. Neuroreport 31 29596155
2023 Integrin β4 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2/IQGAP1/RAC1. eLife 25 37787041
2020 TNFAIP2 Promotes Non-Small Cell Lung Cancer Cells and Targeted by miR-145-5p. DNA and cell biology 23 32456459
2019 TNFAIP2 expression induces epithelial-to-mesenchymal transition and confers platinum resistance in urothelial cancer cells. Laboratory investigation; a journal of technical methods and pathology 22 31263157
2015 TNFAIP2 Inhibits Early TNFα-Induced NF-x03BA;B Signaling and Decreases Survival in Septic Shock Patients. Journal of innate immunity 22 26347487
2011 Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas. The American journal of surgical pathology 20 21921781
2002 Utilization of the human genome sequence localizes human papillomavirus type 16 DNA integrated into the TNFAIP2 gene in a fatal cervical cancer from a 39-year-old woman. Clinical cancer research : an official journal of the American Association for Cancer Research 19 11839676
2014 A functional TNFAIP2 3'-UTR rs8126 genetic polymorphism contributes to risk of esophageal squamous cell carcinoma. PloS one 18 25383966
2022 Tnfaip2 promotes atherogenesis by enhancing oxidative stress induced inflammation. Molecular immunology 17 36084515
2020 Tnfaip2/exoc3-driven lipid metabolism is essential for stem cell differentiation and organ homeostasis. EMBO reports 17 33300287
2024 TNFAIP2 promotes HIF1α transcription and breast cancer angiogenesis by activating the Rac1-ERK-AP1 signaling axis. Cell death & disease 13 39532855
2021 Functional miR-142a-3p Induces Apoptosis and Macrophage Polarization by Targeting tnfaip2 and glut3 in Grass Carp (Ctenopharyngodon idella). Frontiers in immunology 13 34262558
2016 Genome-wide Chromatin Profiling of Legionella pneumophila-Infected Human Macrophages Reveals Activation of the Probacterial Host Factor TNFAIP2. The Journal of infectious diseases 13 27130431
2019 Translation of TNFAIP2 is tightly controlled by upstream open reading frames. Cellular and molecular life sciences : CMLS 10 31392347
2025 TNFAIP2 promotes NF-κB signaling mediate lymph node metastasis of oral squamous cell carcinoma by protecting IKKβ from ubiquitin proteasome degradation. Cell communication and signaling : CCS 8 39948570
2025 Identification of TNFAIP2 as a unique cellular regulator of CSF-1 receptor activation. Life science alliance 7 39939179
2023 Targeting TNFAIP2 induces immunogenic cell death and sensitizes glioblastoma multiforme to anti-PD-1 therapy. Journal of neuro-oncology 6 37819535
2024 TNFAIP2 as an emerging therapeutic target in cancer therapy and its underlying mechanisms. Pharmacological research 5 38688431
2020 Genetic polymorphisms of PGF and TNFAIP2 genes related to cervical cancer risk among Uygur females from China. BMC medical genetics 5 33109108
2025 Acrylamide-induced noradrenergic axon degeneration is promoted via a non-cell autonomous mechanism, involving microglial Tnfaip2/TNF-α and oxidative stress pathways. Journal of hazardous materials 4 40664071
2025 TGF-β-induced acetylation of KLF5 drives TNFAIP2 transcription and EMT in nasopharyngeal carcinoma: Unveiling a novel regulatory mechanism. Experimental cell research 2 40054652
2025 TNFAIP2 deficiency drives formation of an immunosuppressive tumor microenvironment and confers resistance to anti-PD-1 therapy in skin cutaneous melanoma. Scientific reports 2 40664878
2024 The miR-146b-3p/TNFAIP2 axis regulates cell differentiation in acute myeloid leukaemia. Aging 1 38271140
2022 Susceptibility of TNFAIP8, TNFAIP8L1, and TNFAIP2 Gene Polymorphisms on Cancer Risk: A Comprehensive Review and Meta-Analysis of Case-Control Studies. Technology in cancer research & treatment 1 36254562
2026 Human umbilical cord mesenchymal stem cell delivery of mitochondria to melanocytes enhances skin repigmentation efficacy in autologous epidermal cell suspension transplantation through the TNFAIP2-TNT system. International journal of biological sciences 0 41694594
2025 Targeting TNFAIP2 with NIR-II CRISPR-Cas9 nanosystem to overcome cisplatin resistance in laryngeal cancer. NPJ precision oncology 0 40731142
2025 TNFAIP2 increases macrophage response to CSF-1 through multiple effects on CSF-1 receptor. Journal of leukocyte biology 0 41158107

Missed literature

Know a paper Affinage missed for TNFAIP2? Flag it for the maintainers and the community.

No submissions yet.